Amgen Inc.NASDAQ: AMGN

Approach to AI-Enabled Clinical Development

· Issued by Amgen Inc.
The path from molecule to medicine is among the most demanding in science-a long, complex journey where every delay and setback is felt most by patients who are waiting for new treatments. [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Company analysis